GenomeRNAi - a database for RNAi phenotypes and reagents
TitleScreen TitleAssayBiomodelSpecies
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Brummelkamp et al. (2003) NF-kappaB signaling NF-kappaB signalingU2OS (Osteosarcoma)H. sapiens

Abstract

Protein modification by the conjugation of ubiquitin moieties--ubiquitination--plays a major part in many biological processes, including cell cycle and apoptosis. The enzymes that mediate ubiquitin-conjugation have been well-studied, but much less is known about the ubiquitin-specific proteases that mediate de-ubiquitination of cellular substrates. To study this gene family, we designed a collection of RNA interference vectors to suppress 50 human de-ubiquitinating enzymes, and used these vectors to identify de-ubiquitinating enzymes in cancer-relevant pathways. We report here that inhibition of one of these enzymes, the familial cylindromatosis tumour suppressor gene (CYLD), having no known function, enhances activation of the transcription factor NF-kappaB. We show that CYLD binds to the NEMO (also known as IKKgamma) component of the IkappaB kinase (IKK) complex, and appears to regulate its activity through de-ubiquitination of TRAF2, as TRAF2 ubiquitination can be modulated by CYLD. Inhibition of CYLD increases resistance to apoptosis, suggesting a mechanism through which loss of CYLD contributes to oncogenesis. We show that this effect can be relieved by aspirin derivatives that inhibit NF-kappaB activity, which suggests a therapeutic intervention strategy to restore growth control in patients suffering from familial cylindromatosis.

Screen details


Stable Id: GR00111-A-0
Screen title: NF-kappaB signaling
Assay: NF-kappaB signaling
Method: Dual luciferase
Scope:
Screen type: Cell-based
Species: Homo sapiens
Biosource: Cell line
Biomodel: U2OS (Osteosarcoma)
Library: , Custom-made library
Reagent type: shRNA
Score type: np
Cutoff: np
Notes: